Contribution of Bleeding and Thromboembolic Events to In-Hospital Mortality Among Patients With Thrombocytopenia Treated With Heparin

E. Marc Jolicoeur, E. Magnus Ohman, Emily Honeycutt, Richard C. Becker, Eric M. Crespo, Gustavo B.F. Oliveira, David J. Moliterno, Kevin J. Anstrom, Christopher B. Granger

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

In a population of patients experiencing thrombocytopenia while treated with heparin, bleeding and thromboses are well-appreciated complications, but their relative contributions to mortality have been less well described. In this population, the aims of this study were (1) to identify the independent predictors of bleeding and (2) to compare the incidence and the strength of association of bleeding and of new thromboses to in-hospital mortality. The independent predictors of bleeding and in-hospital mortality were identified using multivariate logistic regression models on the 1,478 patients who developed thrombocytopenia after their enrollment in the Complications After Thrombocytopenia Caused by Heparin (CATCH) study. The independent predictors of bleeding were chronic hematologic disorders, intra-aortic balloon pump, congestive heart failure, and platelet count nadir <120 × 109/L. Although bleeding (n = 141 [10%]) and thromboembolic complications (n = 135 [9%]) were equally prevalent, the former was less strongly associated than the latter with in-hospital mortality (odds ratio 1.75, 95% confidence interval 1.01 to 3.03, and odds ratio 2.77, 95% confidence interval 1.67 to 4.61, respectively). In conclusion, medical management should be directed mainly at the prevention of thromboembolic complications, while additionally considering the risk for bleeding.

Original languageEnglish
Pages (from-to)292-297
Number of pages6
JournalAmerican Journal of Cardiology
Volume104
Issue number2
DOIs
StatePublished - Jul 15 2009

Bibliographical note

Funding Information:
The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry was funded by Berlex Laboratories, Inc., Seattle, Washington. Statistical analyses of the CATCH database were funded by The Medicines Company, Parsippany, New Jersey.

Funding

The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry was funded by Berlex Laboratories, Inc., Seattle, Washington. Statistical analyses of the CATCH database were funded by The Medicines Company, Parsippany, New Jersey.

FundersFunder number
Berlex Laboratories, Inc.
Medicines Company

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Contribution of Bleeding and Thromboembolic Events to In-Hospital Mortality Among Patients With Thrombocytopenia Treated With Heparin'. Together they form a unique fingerprint.

    Cite this